Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025